Comparison Study of Dendritic Cell Vaccine with and without Cyclophosphamide to Treat Stage IV Melanoma Patients

December 18, 2009

This trial is evaluating whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Study Type: Interventional

Age/Sex Requirement: 21-75 years (None)

Sponsor: Baylor Research Institute

ClinicalTrials.gov Identifier: NCT00722098

Purpose: To determine whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Click here to learn more about the clinical trial.